Darolutamide Plus Docetaxel for Metastatic HSPC

In light of the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, E. David Crawford, MD, discussed the research that paved the way for the regulatory decision and where future efforts need to be focused.

Patients with metastatic hormone-sensitive prostate cancer can now receive treatment with oral darolutamide plus docetaxel following its approval by the FDA.

In an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.